Risk of Persistent Disability in Patients With Pediatric-Onset Multiple SclerosisDamiano Baroncini, Diana Ferraro, Matilde Inglese et al.|JAMA Neurology|2021Cited by 62
Real world experience with teriflunomide in multiple sclerosis: the TER-Italy studySebastiano Bucello, Luca Prosperini, Pietro Annovazzi et al.|Journal of Neurology|2021Cited by 22
Disease-Modifying Treatments and Time to Loss of Ambulatory Function in Patients With Primary Progressive Multiple SclerosisEmilio Portaccio, Nicola Renato Pizio, Mattia Fonderico et al.|JAMA Neurology|2022Cited by 17
COVID-19 outbreak in Italy: an opportunity to evaluate extended interval dosing of ocrelizumab in MS patientsAlvino Bisecco, Daniela Cargnelutti, Federica Matrone et al.|Journal of Neurology|2023Cited by 12
Long-term effectiveness of natalizumab in secondary progressive multiple sclerosis: A propensity-matched studyClara Grazia Chisari, Maurizia Gatto, Umberto Aguglia et al.|Neurotherapeutics|2024Cited by 7